Literature DB >> 26573841

The diffusion of generics after patent expiry in Germany.

Katharina Elisabeth Fischer1, Tom Stargardt2.   

Abstract

To identify the influences on the diffusion of generics after patent expiry, we analyzed 65 generic entries using prescription data of a large German sickness fund between 2007 and 2012 in a sales model. According to theory, several elements are responsible for technology diffusion: (1) time reflecting the rate of adaption within the social system, (2) communication channels, and (3) the degree of incremental innovation, e.g., the modifications of existing active ingredient's strength. We investigated diffusion in two ways: (1) generic market share (percentage of generic prescriptions of all prescriptions of a substance) and, (2) generic sales quantity (number of units sold) over time. We specified mixed regression models. Generic diffusion takes considerable time. An average generic market share of about 75 % was achieved not until 48 months. There was a positive effect of time since generic entry on generic market share (p < 0.001) and sales (p < 0.001). Variables describing the communication channels and the degree of innovation influenced generic market share (mostly p < 0.001), but not generic sales quantity. Market structure, e.g., the number of generic manufacturers (p < 0.001) and prices influenced both generic market share and sales. Imperfections in generic uptake through informational cascades seem to be largely present. Third-party payers could enhance means to promote generic diffusion to amplify savings through generic entry.

Keywords:  Generic entry; Generic market share; Market regulation; Off-patent markets; Pharmaceutical industry; Product life cycle

Mesh:

Substances:

Year:  2015        PMID: 26573841     DOI: 10.1007/s10198-015-0744-3

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  20 in total

Review 1.  Authorized generic drugs, price competition, and consumers' welfare.

Authors:  Ernst R Berndt; Richard Mortimer; Ashoke Bhattacharjya; Andrew Parece; Edward Tuttle
Journal:  Health Aff (Millwood)       Date:  2007 May-Jun       Impact factor: 6.301

2.  Therapeutic substitution post-patent expiry: the cases of ACE inhibitors and proton pump inhibitors.

Authors:  Sotiris Vandoros
Journal:  Health Econ       Date:  2013-05-21       Impact factor: 3.046

3.  Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.

Authors:  Song Hee Hong; Marvin D Shepherd; David Scoones; Thomas T H Wan
Journal:  J Manag Care Pharm       Date:  2005 Nov-Dec

4.  Generic substitution, financial interests, and imperfect agency.

Authors:  Maurus Rischatsch; Maria Trottmann; Peter Zweifel
Journal:  Int J Health Care Finance Econ       Date:  2013-03-14

5.  Price regulation and relative delays in generic drug adoption.

Authors:  Joan Costa-Font; Alistair McGuire; Nebibe Varol
Journal:  J Health Econ       Date:  2014-04-18       Impact factor: 3.883

6.  State generic substitution laws can lower drug outlays under Medicaid.

Authors:  William H Shrank; Niteesh K Choudhry; Jessica Agnew-Blais; Alex D Federman; Joshua N Liberman; Jun Liu; Aaron S Kesselheim; M Alan Brookhart; Michael A Fischer
Journal:  Health Aff (Millwood)       Date:  2010-07       Impact factor: 6.301

7.  Brand loyalty, patients and limited generic medicines uptake.

Authors:  Joan Costa-Font; Caroline Rudisill; Stefanie Tan
Journal:  Health Policy       Date:  2014-01-28       Impact factor: 2.980

8.  Cumulative changes in the use of long-term medications: a measure of prescribing complexity.

Authors:  Khoa D Lam; Yinghui Miao; Michael A Steinman
Journal:  JAMA Intern Med       Date:  2013-09-09       Impact factor: 21.873

9.  Different initiatives across Europe to enhance losartan utilization post generics: impact and implications.

Authors:  James C Moon; Brian Godman; Max Petzold; Samantha Alvarez-Madrazo; Kathleen Bennett; Iain Bishop; Anna Bucsics; Ulrik Hesse; Andrew Martin; Steven Simoens; Corinne Zara; Rickard E Malmström
Journal:  Front Pharmacol       Date:  2014-10-08       Impact factor: 5.810

Review 10.  A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.

Authors:  Suzanne Dunne; Bill Shannon; Colum Dunne; Walter Cullen
Journal:  BMC Pharmacol Toxicol       Date:  2013-01-05       Impact factor: 2.483

View more
  7 in total

1.  Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany.

Authors:  Afschin Gandjour; Dennis A Ostwald
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

2.  Attitude and Purchase Intention to Generic Drugs.

Authors:  Ricardo Arcaro; Cássia Rita Pereira da Veiga; Wesley Vieira da Silva; Claudimar Pereira da Veiga
Journal:  Int J Environ Res Public Health       Date:  2021-04-26       Impact factor: 3.390

3.  Evaluation of pharmaceutical concerns in Germany: frequency and potential reasons.

Authors:  Gabriele Gradl; Eva-Maria Krieg; Martin Schulz
Journal:  Pharm Pract (Granada)       Date:  2016-09-15

4.  The risk-value trade-off: price and brand information impact consumers' intentions to purchase OTC drugs.

Authors:  Lisa Aufegger; Celine Yanar; Ara Darzi; Colin Bicknell
Journal:  J Pharm Policy Pract       Date:  2021-01-25

5.  Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019.

Authors:  Matthäus Lottes; Viviane Bremer; Christof Prugger; Christian Kollan; Daniel Schmidt
Journal:  BMC Health Serv Res       Date:  2022-01-13       Impact factor: 2.655

6.  Who initiates price competition when generic entrants are introduced into the South Korean pharmaceutical market?

Authors:  Kyung-Bok Son
Journal:  Front Public Health       Date:  2022-09-14

7.  Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate.

Authors:  Jeewon Park; SeungJin Bae; Tae-Jin Lee; Kyung-Bok Son
Journal:  Front Pharmacol       Date:  2020-03-06       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.